| Literature DB >> 26380266 |
Natália Martins1, Lillian Barros2, Mariana Henriques3, Sónia Silva3, Isabel C F R Ferreira2.
Abstract
Candida species have increasingly deserved a special attention among the medical community. In spite of the presence of Candida species as a human commensal, alarming rates of local and systemic infections have been observed, varying from moderate to severe impact. Currently available antifungal drugs have progressively lost their effectiveness, pointing urgently the problem of the microorganisms with acquired-resistance. Natural matrices are secularly used for numerous purposes, being inclusive and highly effective as antimicrobials. Increasing evidence gives a particular emphasis to the contribution of phenolic extracts and related individual compounds. In vitro studies clearly confirm their prominent effects, but the confirmation through in vivo studies, including the involved mechanisms of action, is not so much deepened. Therefore, the present report aims to provide extensive knowledge about all these aspects, highlighting the most efficient phytochemical formulations, including therapeutic doses. Further studies need to be incited to deepen knowledge on this area, namely, focused on clinical trials to provide safer and more effective antimicrobials than the current ones.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26380266 PMCID: PMC4561301 DOI: 10.1155/2015/247382
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Phenolic extracts with in vivo activity against Candida species.
| Family | Species | Part | Preparation | Condition |
| Animal model | Exposure | Doses | Bioactive | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| Acanthaceae |
| Leaves | Methanol extract | Wound healing |
| Sprague-Dawley rats | 24 hours, 24 days | 7.5% w/w extract aqueous cream | Alkaloids, flavonoids, steroids, carbohydrates, sapogenetic glycosides, and tannins | [ |
|
| ||||||||||
| Anacardiaceae |
| Leaves | Methanol extract | Wound healing |
| Sprague-Dawley rats | 24 hours, 24 days | 7.5% w/w extract aqueous cream | Alkaloids, flavonoids, steroids, carbohydrates, sapogenetic glycosides, and tannins | [ |
|
| ||||||||||
| Arecaceae |
| Leaves | Methanol extract | Antifungal potential |
| Swiss albino mice | Once daily during 7 days | Oral administration: 2.5 g/kg body weight | Phenols | [ |
|
| ||||||||||
| Bignoniaceae |
| Flowers | Methanol extract | Antimicrobial and wound healing potential |
| Wistar rats | 19 days | 100 mg/kg body weight | n.d. | [ |
|
| ||||||||||
| Caprifoliaceae |
| Flowering aerial parts | Ethanol extract | Antiwound infection, repair, and contraction |
| Wistar rats | 15 days | 10% (w/w) LJEE ointment | Chlorogenic acid | [ |
|
| ||||||||||
| Combretaceae |
| Leaves | Acetone extract | Wound healing and antifungal potential |
| Immunosuppressed Wistar rats | 3 times a week, during 17 days | 20% in aqueous cream | n.d. | [ |
|
| ||||||||||
| Eriocaulaceae |
| Scapes | Methanol extract | Vulvovaginal candidiasis |
| Wistar rats | 2 times per day, 7 days | Cream with 0.5%, 1.0%, and 2.0% of extract | Flavonoids, flavone derivatives | [ |
|
| ||||||||||
| Leguminosae |
| Seeds | Methanol extract | Anticandidal potential |
| Swiss albino mice | Once daily, during 3 days | 2.5 g/kg body weight (intraperitoneal) | n.d. | [ |
|
| ||||||||||
| Meliaceae |
| Seeds | Methanol extract | Antifungal potential |
| Mice | 7 days | 2.5 g/kg of extract (intraperitoneal) | Saponins, phenols, volatile oils, alkaloids, anthraquinones, and terpenoids | [ |
|
| ||||||||||
| Moraceae |
| Fruit and bark | Methanol extract | Immunomodulatory potential |
| Swiss albino mice | 13 days | 250 and 500 mg/kg p.o | Carbohydrates, glycosides, wax, steroids, saponins, and tannins | [ |
|
| ||||||||||
| Olacaceae |
| Fruits | Methanol-dichloromethane (3 : 1 v/v) extract | Anti- |
| Female albino Wistar rats | 3 days | 0.5, 1 and 2 g/kg of body weight, i.v. administration | n.d. | [ |
|
| ||||||||||
| Parmeliaceae |
| Lichens (thallus) | Methanol, dichloromethane, ethyl acetate, and n-butanol extracts | Anti-inflammatory, antinociceptive, and wound healing potential |
| Sprague-Dawley rats and Swiss albino mice | Between 60 min and 9 days, according to the studied bioactivity1 | Oral administration and topical use | Isolated compounds: atraric acid, mixture of methyl hematommate and methyl chlorohematommate | [ |
|
| ||||||||||
| Poaceae |
| Leaves | Ethyl acetate fraction of the alcoholic extract | Immunomodulatory potential |
| BALB/C mice | 5 days | Oral administration: 50–200 mg/Kg body weight | Isoorientin, orientin, and isovitexin | [ |
|
| ||||||||||
| Polygonaceae |
| Leaves | Cooked leaves | Anti- |
| Lactating cows of three farms | 5 days | 1.5 kg/day | n.d. | [ |
|
| ||||||||||
| Punicaceae |
| Peels | Aqueous: methanol (75%) extract | Wound healing potential |
| Guinea pigs | Once daily during 10 days | 5% (w/w) methanolic extract based ointment, using soft white paraffin, as vehicle | Ellagitannins (punicalagin A, punicalagin B, gallic acid, and ellagic acid), followed by anthocyanidins | [ |
|
| ||||||||||
| Salvadoraceae |
| Chewing sticks | Methanol extract | Oral health of children presenting decays |
| School children aged between 6 and 12 years | 1 week | Mouthwash | Phenolic compounds | [ |
|
| ||||||||||
| Verbanaceae |
| Plant material | Methanolic extract | Wound healing and antifungal effects |
| Sprague-Dawley rats | 9 days | 100 mg of ointment (33.3% w/w | Reducing sugars, phytosterols, tannins, terpenoids, alkaloids, and flavonoids | [ |
|
| ||||||||||
| Vitaceae |
| Seeds | Ethanol : water (7 : 3 v/v) extract | Antifungal potential (vaginal candidiasis model) |
| CD1 mice | Every two days, until day +8 | 10 | Mixture of monomeric, oligomeric, and polymeric flavan-3-ols | [ |
|
| ||||||||||
| Zygophyllaceae |
| Leaves and tender branches | 3 fractions of the aqueous extract | Immunomodulatory potential (innate immunity enhancer) |
| Rockland mice | twice in a 48-hour period | 0.5, 5 and 15 mg kg−1 of fractions, intraperitoneal | n.d. | [ |
1Anti-inflammatory: every 90 min during 6 h after induced inflammation, antinociceptive: 60 min after oral administration of test samples, counted for the following 15 min (starting 5 min after the PBQ injection), wound healing activity: once a day, during 9 days, and n.d.: not determined/detailed.
Phenolic compounds with in vivo activity against Candida species.
| Compound | Class | Origin | Condition |
| Purpose | Animal model | Exposure | Doses | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Curcuminoids: curcumin and piperine | Polyphenols | Commercial standards | Systemic murine model of infection |
| Antifungal potential and related modes of action | Swiss albino mice | 1st dose + 2nd dose after 6 h of the first, during 2 days | Curcumin alone: 100 mg/kg of body weight | [ |
|
| |||||||||
| Pterostilbene (PTE) | Stilbene-derived Phytoalexin | Laboratorial synthesis | Central venous catheter infection |
| Antibiofilm potential | Sprague-Dawley rats | 72 h of incubation | 500 | [ |
|
| |||||||||
| Riccardin D (RCD) | Macrocyclic bisbibenzyl | Chinese liverwort | Intravenous catheter infection |
| Antibiofilm (prophylactic and therapeutic) potential | New Zealand white rabbits | Prophylactic: 8 h | Prophylactic: Groups II, III, and IV, 300 | [ |
Figure 1Chemical structures of the tested bioactive molecules with in vivo anti-Candida potential.
Figure 2Mechanisms of action of the in vivo tested phenolic extracts and compounds against Candida species.
Phytochemical preparations evaluated through in vivo laboratorial models.
| Application |
| Type of formulation | Reference |
|---|---|---|---|
| Intraperitoneal | Immunomodulation | Solution (water) | [ |
| Intravenous | Solution (methanol) | [ | |
| Suspension (methanol) | [ | ||
|
| |||
| Intravaginal | Vaginal infection | Cream (o/w emulsion) | [ |
| Suspension | [ | ||
|
| |||
| Intravenous | Intravenous | Solution (water) | [ |
|
| |||
| Orally | Anti-inflammation, antinociceptive and would healing potential (incision/excision models) | Suspension (0.5% sodium carboxy methyl cellulose (CMC)) | [ |
| Excision and incision wound | Suspension (extract in vehicle) | [ | |
| Immunomodulation | Suspension (1% sodium carboxy methyl cellulose (CMC)) | [ | |
| Suspension (1% w/v aqueous gum acacia) | [ | ||
| Intravenous | Solution (aqueous) | [ | |
| Oral cavity children affections | Mouthwash (water) | [ | |
| Subclinical mastitis | Crude extracts (cooked and powder leaves) | [ | |
|
| |||
| Topically | Excision and incision wound | Ointment (vehicle) | [ |
| Cream (aqueous) | [ | ||
| Excision wound | Cream (aqueous) | [ | |
| Ointment (w/w) | [ | ||
| Ointment (w/w) | [ | ||
| Ointment (vehicle) | [ | ||